نتایج جستجو برای: hdac inhibitor

تعداد نتایج: 213269  

Journal: :Molecules 2018
Kristina King Alexander-Thomas Hauser Jelena Melesina Wolfgang Sippl Manfred Jung

We designed and synthesized carbamates of the clinically-approved HDAC (histone deacetylase) inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) in order to validate our previously-proposed hypothesis that these carbamates might serve as prodrugs for hydroxamic acid containing HDAC inhibitors. Biochemical assays proved our new compounds to be potent inhibitors of histone deacetylases i...

Journal: :FEBS letters 2007
Longchuan Bai Juanita L Merchant

A thorough understanding of histone acetyltransferase CBP/p300-mediated regulation of gene expression and cell growth is essential to identify mechanisms relevant to the development of histone deacetylase (HDAC) inhibitor-based preventive and therapeutic strategies. We found that knockdown of CBP/p300 interacting coactivator with glutamic acid/aspartic acid-rich tail 2 (CITED2) increased colon ...

Journal: :Molecular cancer research : MCR 2004
Mauro Bordin Fabio D'Atri Laurent Guillemot Sandra Citi

Histone deacetylase (HDAC) inhibitors promote cell maturation, differentiation, and apoptosis through changes in gene expression. Differentiated epithelial cells are characterized by apical tight junctions (TJ), which play a role in cell-cell adhesion, polarity, and the permeability barrier function of epithelia. The relationship between cellular differentiation and expression of TJ-associated ...

Journal: :Journal of gynecologic oncology 2010
Ke Long Jin Jeong-Yeol Park Eun Joo Noh Kwang Lae Hoe Joo Hak Lee Jong-Hyeok Kim Joo-Hyun Nam

OBJECTIVE To investigate the combined effects of cisplatin and the histone deacetylase (HDAC) inhibitors suberoylanilide hydroxamic acid (SAHA) or sirtinol on HeLa cells and assess the mechanism underlying HDAC inhibitor-cisplatin synergy. METHODS The antineoplastic actions of cisplatin, SAHA and sirtinol, alone and in combination, were evaluated using the tetrazolium dye-based MTT cell proli...

2010
Alfonso Dueñas-Gonzalez Maria Teresa Vega Déborah Martinez-Baños Linda García-Hidalgo Pedro Sobrevilla

Histone deacetylase (HDAC) inhibitors have shown significant activity in the treatment of cutaneous T-cell lymphomas (CTCL). The epigenetic alterations of CTCL not only are limited to altered histone acetylation but also include aberrant DNA gene methylation hence, the combination of an HDAC inhibitor with a DNA demethylating agent is a promising therapy to be tested. Here we report a mycosis f...

Journal: :Proceedings of the National Academy of Sciences of the United States of America 2008
Cynthia K Hahn Kenneth N Ross Ian M Warrington Ralph Mazitschek Cindy M Kanegai Renee D Wright Andrew L Kung Todd R Golub Kimberly Stegmaier

The discovery of new small molecules and their testing in rational combination poses an ongoing problem for rare diseases, in particular, for pediatric cancers such as neuroblastoma. Despite maximal cytotoxic therapy with double autologous stem cell transplantation, outcome remains poor for children with high-stage disease. Because differentiation is aberrant in this malignancy, compounds that ...

Journal: :Molecular cancer therapeutics 2009
Douglas C Marchion Elona Bicaku Joel G Turner Morgen L Schmitt Dawn R Morelli Pamela N Munster

Histone deacetylases (HDAC) may have a prominent role in the development of cancer and the response to anticancer therapy. However, the therapeutic relevance and tissue specificity of individual HDAC enzymes remain largely unknown. HDAC inhibitors may function as sensitizing agents to chemotherapies that target DNA through their effects on chromatin structure and plasticity. Here, we report a n...

2017
Eva Juengel Ramin Najafi Jochen Rutz Sebastian Maxeiner Jasmina Makarevic Frederik Roos Igor Tsaur Axel Haferkamp Roman A. Blaheta

Introduction Although the mechanistic target of rapamycin (mTOR) might be a promising molecular target to treat advanced bladder cancer, resistance develops under chronic exposure to an mTOR inhibitor (everolimus, temsirolimus). Based on earlier studies, we proposed that histone deacetylase (HDAC) blockade might circumvent resistance and investigated whether HDAC inhibition has an impact on gro...

Journal: :Molecular cancer therapeutics 2008
Marielle Fournel Claire Bonfils Yu Hou Pu Theresa Yan Marie-Claude Trachy-Bourget Ann Kalita Jianhong Liu Ai-Hua Lu Nancy Z Zhou Marie-France Robert Jeffrey Gillespie James J Wang Hélène Ste-Croix Jubrail Rahil Sylvain Lefebvre Oscar Moradei Daniel Delorme A Robert Macleod Jeffrey M Besterman Zuomei Li

Nonselective inhibitors of human histone deacetylases (HDAC) are known to have antitumor activity in mice in vivo, and several of them are under clinical investigation. The first of these, Vorinostat (SAHA), has been approved for treatment of cutaneous T-cell lymphoma. Questions remain concerning which HDAC isotype(s) are the best to target for anticancer activity and whether increased efficacy...

2015
Takayo Fukuda Wenwen Wu Maiko Okada Ichiro Maeda Yasuyuki Kojima Ryosuke Hayami Yasuo Miyoshi Ko-ichiro Tsugawa Tomohiko Ohta

BRCA1 and 53BP1 antagonistically regulate homology-directed repair (HDR) and non-homologous end-joining (NHEJ) of DNA double-strand breaks (DSB). The histone deacetylase (HDAC) inhibitor trichostatin A directly inhibits the retention of 53BP1 at DSB sites by acetylating histone H4 (H4ac), which interferes with 53BP1 binding to dimethylated histone H4 Lys20 (H4K20me2). Conversely, we recently fo...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید